Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:09:26 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



News for U:ALVO from 2023-05-09 to 2024-05-08 - 46 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:15U:ALVONews ReleaseAlvotech Announces Participation at BofA Securities Healthcare Conference 2024
2024-04-30 04:00U:ALVONews ReleaseU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira(TM) (adalimumab)
2024-04-30 04:00U:ALVONews ReleaseU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira(TM) (adalimumab)
2024-04-24 04:00U:ALVONews ReleaseAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi(TM) (golimumab)
2024-04-19 06:10U:ALVONews ReleaseAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira(TM) (adalimumab)
2024-04-16 17:43U:ALVONews ReleaseAlvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(TM) (ustekinumab)
2024-04-16 17:30U:ALVONews ReleaseAlvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(TM) (ustekinumab)
2024-04-03 07:41U:ALVONews ReleaseAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
2024-03-22 16:15U:ALVONews ReleaseAlvotech Announces Increase in Number of Own Shares
2024-03-20 16:15U:ALVONews ReleaseAlvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
2024-03-05 16:00U:ALVONews ReleaseAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
2024-02-29 16:05U:ALVONews ReleaseAlvotech Appoints Interim Chief Quality Officer
2024-02-26 04:25U:ALVONews ReleaseAlvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
2024-02-23 20:15U:ALVONews ReleaseAlvotech and Teva Announce U.S. Approval of SIMLANDI(TM) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(TM)
2024-02-23 20:15U:ALVONews ReleaseAlvotech and Teva Announce U.S. Approval of SIMLANDI(TM) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(TM)
2024-02-15 06:30U:ALVONews ReleaseAlvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara ‚ ® (ustekinumab)
2024-01-29 04:00U:ALVONews ReleaseAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia ‚ ® and Xgeva ‚ ®
2024-01-19 11:30U:ALVONews ReleaseAlvotech Provides Update on Status of ‚  Biologics License Applications for AVT02 and AVT04
2024-01-10 03:30U:ALVONews ReleaseSTADA and Alvotech secure approval for Uzpruvo, Europe ¢ € ™s first ustekinumab biosimilar to Stelara
2024-01-03 03:30U:ALVONews ReleaseAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea ‚ ® (aflibercept)
2023-11-29 04:00U:ALVONews ReleaseAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi ‚ ® and Simponi Aria ‚ ®
2023-11-28 16:15U:ALVONews ReleaseAlvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
2023-11-21 08:00U:ALVONews ReleaseAlvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
2023-11-14 07:00U:ALVONews ReleaseAlvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki ¢ „ ¢ (AVT04), the First Biosimilar of Stelara ‚ ® (ustekinumab)
2023-11-10 09:30U:ALVONews ReleaseSTADA and Alvotech receive positive CHMP opinion for Europe ¢ € ™s first ustekinumab biosimilar to Stelara
2023-11-07 08:00U:ALVONews ReleaseAlvotech to Present at the Jefferies 2023 London Healthcare Conference
2023-10-12 04:00U:ALVONews ReleaseAlvotech Provides Update on Status of U.S. Biologics License Application for AVT04
2023-10-03 08:29U:ALVONews ReleaseKashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair ‚ ® (omalizumab)
2023-10-03 05:00U:ALVONews ReleaseAlvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair ‚ ® (omalizumab)
2023-09-25 04:00U:ALVONews ReleaseAlvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara ‚ ®
2023-09-20 04:30U:ALVONews ReleaseAlvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira ‚ ® (adalimumab)
2023-09-05 09:30U:ALVONews ReleaseAlvotech Announces Changes to the Leadership Team
2023-08-30 16:15U:ALVONews ReleaseAlvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
2023-08-29 05:00U:ALVONews ReleaseAlvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
2023-08-22 09:15U:ALVONews ReleaseAlvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
2023-07-31 04:00U:ALVONews ReleaseAlvotech Completes $100 Million Convertible Bond Private Placement
2023-07-24 04:00U:ALVONews ReleaseTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
2023-06-28 19:00U:ALVONews ReleaseAlvotech Provides Regulatory Update on Second Biologics License Application for AVT02
2023-06-12 07:00U:ALVONews ReleaseAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ‚ ®
2023-06-12 03:00U:ALVONews ReleaseAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ‚ ®
2023-05-31 05:20U:ALVONews ReleaseAlvotech to Participate in Jefferies Healthcare Conference
2023-05-24 05:00U:ALVONews ReleaseAlvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
2023-05-19 05:00U:ALVONews ReleaseAlvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
2023-05-17 05:00U:ALVONews ReleaseAlvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
2023-05-15 05:00U:ALVONews ReleaseAlvotech Issues Annual Equality Report Covering 2022
2023-05-10 05:00U:ALVONews ReleaseAlvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea ‚ ® (aflibercept)